About this trial
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.
The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 18 and 65
Referred for immunisation against yellow fever and typhoid
Yellow fever
Typhoïd
Disqualifiers
Anyone with a contraindication to yellow fever and/or typhoid vaccination.
Any person who has been vaccinated against yellow fever and/or typhoid.
Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid.
Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.
Trial design
Single group
Treatments tested in this trial
blood samples collection
Biological/Vaccineblood samples collected at D0 ,W1, W5, M3 and M6
Treatment groups
Trial outcomes
Primary outcomes
Immunological profile of PBMCs, before and after yellow fever vaccination
Cytokine production assays (e.g. TNFa, IL6, IL1b)
Secondary outcomes
Description of the response to TyphimVi® vaccine
ELISA-based quantification of Anti-Vi antibody level \>30 U/mL at week 5, and/or fold increase ≥2 compared with pre-vaccination IgG titer.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.